Listed

Medline Inc.

MDLNNasdaqCIK 2046386HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$7.68bn, Q2 FY2026
Operating income$395.0m, Q2 FY2026
Net income$139.0m, Q2 FY2026
Medline Inc., income statement, quarterly
Line itemUnitperiod not labelled2025-03-29period not labelled2025-06-28Q1 FY20262026-03-28Q2 FY20262026-06-27
Revenue$m6,644Revenue, period not labelled, three months to 2025-03-29$6.64bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure6,886Revenue, period not labelled, three months to 2025-06-28$6.89bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure7,352Revenue, Q1 FY2026, three months to 2026-03-28$7.35bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure7,685Revenue, Q2 FY2026, three months to 2026-06-27$7.68bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Cost of revenue$m4,820Cost of revenue, period not labelled, three months to 2025-03-29$4.82bn. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure4,981Cost of revenue, period not labelled, three months to 2025-06-28$4.98bn. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure5,511Cost of revenue, Q1 FY2026, three months to 2026-03-28$5.51bn. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure5,470Cost of revenue, Q2 FY2026, three months to 2026-06-27$5.47bn. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Gross profit$m1,824Gross profit, period not labelled, three months to 2025-03-29$1.82bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure1,905Gross profit, period not labelled, three months to 2025-06-28$1.91bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure1,841Gross profit, Q1 FY2026, three months to 2026-03-28$1.84bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure2,215Gross profit, Q2 FY2026, three months to 2026-06-27$2.21bn. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Selling, general and administrative$m1,070Selling, general and administrative, period not labelled, three months to 2025-03-29$1.07bn. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure1,073Selling, general and administrative, period not labelled, three months to 2025-06-28$1.07bn. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure1,228Selling, general and administrative, Q1 FY2026, three months to 2026-03-28$1.23bn. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure1,295Selling, general and administrative, Q2 FY2026, three months to 2026-06-27$1.29bn. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Operating income$m571Operating income, period not labelled, three months to 2025-03-29$571.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure642Operating income, period not labelled, three months to 2025-06-28$642.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure422Operating income, Q1 FY2026, three months to 2026-03-28$422.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure395Operating income, Q2 FY2026, three months to 2026-06-27$395.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Interest expense$m244Interest expense, period not labelled, three months to 2025-03-29$244.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure253Interest expense, period not labelled, three months to 2025-06-28$253.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure165Interest expense, Q1 FY2026, three months to 2026-03-28$165.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure168Interest expense, Q2 FY2026, three months to 2026-06-27$168.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Income tax$m16.0Income tax, period not labelled, three months to 2025-03-29$16.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure26.0Income tax, period not labelled, three months to 2025-06-28$26.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure52.0Income tax, Q1 FY2026, three months to 2026-03-28$52.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure96.0Income tax, Q2 FY2026, three months to 2026-06-27$96.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Net income$m319Net income, period not labelled, three months to 2025-03-29$319.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure329Net income, period not labelled, three months to 2025-06-28$329.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure239Net income, Q1 FY2026, three months to 2026-03-28$239.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure139Net income, Q2 FY2026, three months to 2026-06-27$139.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Diluted EPS$ per sharenot reportednot reported0.16Diluted EPS, Q1 FY2026, three months to 2026-03-28$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure0.07Diluted EPS, Q2 FY2026, three months to 2026-06-27$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Basic EPS$ per sharenot reportednot reported0.16Basic EPS, Q1 FY2026, three months to 2026-03-28$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure0.07Basic EPS, Q2 FY2026, three months to 2026-06-27$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure

Balance sheet

Cash and equivalents$2.33bn, Q2 FY2026
Long-term debt$12.55bn, Q2 FY2026
Shareholders' equity$11.57bn, Q2 FY2026
Medline Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2024-12-31FY20252025-12-31Q1 FY20262026-03-28Q2 FY20262026-06-27
Cash and equivalents$bn0.2Cash and equivalents, period not labelled, at 2024-12-31$199.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-25, accession 0002046386-26-000009.Report this figure1.9Cash and equivalents, FY2025, at 2025-12-31$1.94bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure2.2Cash and equivalents, Q1 FY2026, at 2026-03-28$2.24bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure2.3Cash and equivalents, Q2 FY2026, at 2026-06-27$2.33bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Current assets$bn8.3Current assets, period not labelled, at 2024-12-31$8.27bn. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-25, accession 0002046386-26-000009.Report this figure10.7Current assets, FY2025, at 2025-12-31$10.68bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure11.2Current assets, Q1 FY2026, at 2026-03-28$11.18bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure11.7Current assets, Q2 FY2026, at 2026-06-27$11.74bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Total assets$bn36.0Total assets, period not labelled, at 2024-12-31$35.98bn. XBRL concept us-gaap:Assets. 10-K filed 2026-02-25, accession 0002046386-26-000009.Report this figure38.5Total assets, FY2025, at 2025-12-31$38.48bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure39.0Total assets, Q1 FY2026, at 2026-03-28$39.01bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure39.4Total assets, Q2 FY2026, at 2026-06-27$39.35bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Current liabilities$bn2.4Current liabilities, period not labelled, at 2024-12-31$2.44bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-25, accession 0002046386-26-000009.Report this figure2.5Current liabilities, FY2025, at 2025-12-31$2.49bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure2.5Current liabilities, Q1 FY2026, at 2026-03-28$2.54bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure2.7Current liabilities, Q2 FY2026, at 2026-06-27$2.71bn. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Total liabilities$bn19.5Total liabilities, period not labelled, at 2024-12-31$19.45bn. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-25, accession 0002046386-26-000009.Report this figure19.2Total liabilities, FY2025, at 2025-12-31$19.20bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure19.7Total liabilities, Q1 FY2026, at 2026-03-28$19.66bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure20.3Total liabilities, Q2 FY2026, at 2026-06-27$20.27bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Long-term debt$bn16.4Long-term debt, period not labelled, at 2024-12-31$16.42bn. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-02-25, accession 0002046386-26-000009.Report this figure12.5Long-term debt, FY2025, at 2025-12-31$12.48bn. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure12.5Long-term debt, Q1 FY2026, at 2026-03-28$12.49bn. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure12.5Long-term debt, Q2 FY2026, at 2026-06-27$12.55bn. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Current portion of debt$bn0.1Current portion of debt, period not labelled, at 2024-12-31$76.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-02-25, accession 0002046386-26-000009.Report this figure0.1Current portion of debt, FY2025, at 2025-12-31$76.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure0.1Current portion of debt, Q1 FY2026, at 2026-03-28$76.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure0.0Current portion of debt, Q2 FY2026, at 2026-06-27$28.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Short-term borrowings$bn0.0Short-term borrowings, period not labelled, at 2024-12-31$2.0m. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2026-02-25, accession 0002046386-26-000009.Report this figure0.0Short-term borrowings, FY2025, at 2025-12-31$1.0m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure0.0Short-term borrowings, Q1 FY2026, at 2026-03-28$1.0m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure0.0Short-term borrowings, Q2 FY2026, at 2026-06-27$1.0m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure
Shareholders' equity$bnnot reported10.7Shareholders' equity, FY2025, at 2025-12-31$10.74bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure11.3Shareholders' equity, Q1 FY2026, at 2026-03-28$11.27bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure11.6Shareholders' equity, Q2 FY2026, at 2026-06-27$11.57bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure

Cash flow

Operating cash flow$715.0m, Q2 FY2026
Capital expenditure$111.0m, Q2 FY2026
Share repurchases$0, Q2 FY2026
Medline Inc., cash flow, quarterly
Line itemUnitperiod not labelled2025-03-29period not labelled2025-06-28Q1 FY20262026-03-28Q2 FY20262026-06-27
Operating cash flow$m682Operating cash flow, period not labelled, three months to 2025-03-29$682.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure197Operating cash flow, period not labelled, three months to 2025-06-28$197.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0002046386-26-000051. Derived: 6-month figure less the 3-month figure.Report this figure412Operating cash flow, Q1 FY2026, three months to 2026-03-28$412.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure715Operating cash flow, Q2 FY2026, three months to 2026-06-27$715.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0002046386-26-000051. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m98.0Capital expenditure, period not labelled, three months to 2025-03-29$98.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure110Capital expenditure, period not labelled, three months to 2025-06-28$110.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0002046386-26-000051. Derived: 6-month figure less the 3-month figure.Report this figure96.0Capital expenditure, Q1 FY2026, three months to 2026-03-28$96.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure111Capital expenditure, Q2 FY2026, three months to 2026-06-27$111.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0002046386-26-000051. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$m9.0Share repurchases, period not labelled, three months to 2025-03-29$9.0m. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure6.0Share repurchases, period not labelled, three months to 2025-06-28$6.0m. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-08-05, accession 0002046386-26-000051. Derived: 6-month figure less the 3-month figure.Report this figure0.0Share repurchases, Q1 FY2026, three months to 2026-03-28$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure0.0Share repurchases, Q2 FY2026, three months to 2026-06-27$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-08-05, accession 0002046386-26-000051. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)860.89m, Q2 FY2026
Medline Inc., shares, quarterly
Line itemUnitQ1 FY20262026-03-28Q2 FY20262026-06-27
Diluted shares (weighted)m shares825Diluted shares (weighted), Q1 FY2026, three months to 2026-03-28824,836,037 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0002046386-26-000026.Report this figure861Diluted shares (weighted), Q2 FY2026, three months to 2026-06-27860,890,719 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0002046386-26-000051.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.